Abstract
This study explores the potential for mixture-cure models (MCM) to capture heterogeneity in life expectancy with nivolumab plus ipilimumab (N+I), given the novel mechanism of action and durable, deep survival response, using the CheckMate-227 (CM227) Part 1 trial of advanced non-small cell lung cancer (aNSCLC).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
